Foreign Discovery Mostly Denied In Zofran Birth Defect MDL

Law360, Boston (August 25, 2017, 1:29 PM EDT) -- A Massachusetts federal judge on Thursday mostly rejected efforts by families suing GlaxoSmithKline over alleged links between birth defects and anti-nausea drug Zofran to get access to foreign regulatory files.

The families had said the request could shed light on whether GSK misled the U.S. Food and Drug Administration by comparing what they told American regulators to what they told regulators in Japan, the U.K. and Canada.

U.S. Magistrate Judge Judith Dein said at a hearing that she was mostly going to reject the request but would make GSK answer questions about foreign regulatory files in Japan.

“I don’t have anything...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!